Iterum Therapeutics plc (ITRM)
After hours:
| Previous Close | 1.0800 |
| Open | 1.1500 |
| Bid | 1.0900 x 1100 |
| Ask | 1.1500 x 900 |
| Day's Range | 1.0800 - 1.1650 |
| 52 Week Range | 0.6010 - 7.0500 |
| Volume | |
| Avg. Volume | 100,323 |
| Market Cap | 13.457M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter
- GlobeNewswire
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023.
- GlobeNewswire
Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 2,500 ordinary shares of Iterum Therapeutics as an inducement to a newly hir
